Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.80 |
| ▸ | NPC1 | O15118 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | MTOR | P42345 | 2/20 | 0.80 |
| ▸ | RAB9A | P51151 | 2/20 | 0.80 |
| ▸ | MLNR | O43193 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | ESR1 | P03372 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615190 | 1.00 | CYP3A4 (0.80) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL12562873 | 0.89 | CYP3A4 (0.80) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL22877398 | 0.89 | CYP3A4 (0.80) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL22678743 | 0.89 | CYP3A4 (0.80) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| Sertraline SCHEMBL3885286 | 0.89 | MEN1 (1.00) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| Sertraline SCHEMBL137619 | 0.89 | MEN1 (1.00) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| Sertraline SCHEMBL3947169 | 0.89 | MEN1 (1.00) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| Sertraline SCHEMBL7922153 | 0.89 | MEN1 (1.00) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| Sertraline SCHEMBL3856872 | 0.89 | MEN1 (1.00) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 | |
| Sertraline SCHEMBL14028076 | 0.89 | MEN1 (1.00) | CYP3A4MEN1KMT2ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000926-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000926-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-01-07 | — | — | US | disclosed |
| US-20140171383-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | The Regents of the Univeristy of Colorado, a body corporate | 2014-06-19 | — | — | US | disclosed |
| US-20140171383-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | The Regents of the Univeristy of Colorado, a body corporate | 2014-06-19 | — | — | US | disclosed |
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-03-22 | — | — | US | disclosed |
| US-20090209480-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209480-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209480-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | INA, BDNF, PMP22 | CYP3A4 4102/4885MEN1 1319/4885KMT2A 914/4885 |
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | PMP22, INA, SMN1; SMN2 | CYP3A4 4518/4885MEN1 909/4885KMT2A 1104/4885 |
| US-20140171383-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | INA, BDNF, PMP22 | CYP3A4 4102/4885MEN1 1319/4885KMT2A 914/4885 |
| US-20160000926-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | INA, BDNF, PMP22 | CYP3A4 4102/4885MEN1 1319/4885KMT2A 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.